Purpose: Spexin, a novel peptide, has potential implications in obesity, satiety and energy homeostasis. The current study examined the relationship of spexin with various biomarkers of cardiovascular disease and endothelial function in adolescents with obesity.
Background
Spexin is a novel peptide recently identified by using Markov modelling.(1) The gene encoding spexin (Cg12orf39) is the most down-regulated gene in obese omental and subcutaneous human fat. ( 2) The physiological significance of spexin remains mostly unclear. Previous studies in rat and goldfish have demonstrated expression of spexin mRNA and protein in several tissues including the hypothalamus, hippocampus, cerebral cortex, stomach, kidney, adrenal gland and ovary. (3, 4) Notably, circulating spexin concentrations are lower in children and adults with obesity than in their lean counterparts. (5, 6) Previous animal studies have also described spexininduced weight loss in rodents with diet-induced obesity (DIO).(5,7) Studies in humans on spexin are sparse, and Walewski et al. reported an inverse association between spexin and leptin.(5) Although in a previous study in children we reported spexin's ability to discriminate between lean and obese children, (6) its potential physiological role in children and adolescents with obesity and/or its relationships with satiety hormones, biomarkers of cardiovascular disease (CVD) and endothelial dysfunction are less clear. The objective of the current study was to examine the relationship between spexin and leptin along with specific biomarkers of CVD and endothelial function in adolescents with obesity.
Materials and methods
After obtaining approval from the Institutional Review Board of Mayo Clinic, Rochester, MN and consents from participants and parents, a total of 19 adolescents with BMI at or above the 95th percentile (age, 15.8 ± 1.7 years) were studied. Sample size calculation was not performed a priori due to scant data on spexin, especially in children. Study design and other details can be found in detail in our previous study. (8) Height, weight and blood pressure were obtained after overnight fast. Study participants were normotensive and non-diabetic.
Biochemical measurements
Blood samples were obtained after overnight fast of 12 h. The measurements included spexin, leptin, glucose, insulin, lipid profile, high-sensitivity C-reactive protein (hs-CRP), total adiponectin and high molecular weight adiponectin. Spexin was measured by using a specific enzyme-linked immunoassay from Phoenix Pharmaceuticals, Inc, Burlingame, CA. The intraassay and interassay coefficients of variation for spexin were ≤0 and ≤15 per cent, respectively. The assay sensitivity was 0.11 ng/mL with a linear range of 0.11-1.07 ng/mL. Glucose was measured by oxidase method (Analox Glucose Analyser; Analox Instruments); insulin by using commercial electrochemiluminescence immunoassay kits (Roche E Modular, Roche Diagnostics, Indianapolis, IN); total and high molecular weight adiponectin and leptin by enzyme-linked immunoassay (R&D Systems Inc., Minneapolis, MN); and total cholesterol, high density lipoprotein cholesterol and triglycerides by enzymatic colorimetric assay (Roche Diagnostics, Indianapolis, IN), and low-density lipoprotein cholesterol was calculated. Hs-CRP was measured by using particleenhanced immunonephelometry (Siemens Healthcare Diagnostics, Deerfield, IL). A concentration of CRP >3 mg/L was considered high risk (9) (10) (11) (12) for data analysis.
The homeostatic model assessment insulin resistance (HOMA-IR) index was calculated as HOMA-IR = fasting serum glucose (mmol/L) × fasting insulin (mcIU/mL)/22.5.
Assessment of endothelial function
Endothelial function was assessed by high-resolution Doppler ultrasonography examination of the right brachial artery as previously reported. (8) 
Statistical analysis
Demographics, clinical characteristics and biochemical measurements were summarized by mean (standard deviation) or median (interquartile range [IQR]). Pearson correlation or Spearman rank correlation was performed, as appropriate, to examine the association of spexin with leptin as well as with various biochemical measurements and brachial artery flow-mediated dilation (FMD).
A principal component (PC) analysis was performed to combine the concurring characteristics of spexin and leptin levels. PCs are independent linear combinations based on the patterns of the correlations of the original variables. PCs are structured by the magnitude of the total variability in the data set that they represent, such that the first PC (PC1) accounts for highest proportion of the total variance, followed by PC2 and so on. In case of two correlated variables, PC1 represents the concurring characteristics of the two variables. In the current study, both spexin and leptin met all assumptions for PC and a scatterplot of these two variables showed an estimated linear relationship between them. There were no outliers, and the variables were not significantly deviated from the normality (P > 0.05 for Shapiro-Wilk test). A value of 0.7 for Kaiser-Meyer-Olkin test indicated the sampling adequacy of the data. A significant Bartlett test of sphericity (P = 0.03) justified the application of PC analysis of these two correlated variables. PC1 represents more than 75 per cent of the variation in the data of these two variables. Spearman rank correlation or Pearson correlation coefficient, as appropriate, was used to examine the association between PC1 and cardiometabolic biomarkers. A two-sample test was used to compare the mean score of PC1 between the two groups based on hs-CRP concentration: one group with hs-CRP > 3 mg/L, which represented greater risk for CVD, and the other group with hs-CRP < 3 mg/L with relatively lower risk for CVD. A cluster analysis of PC1 was performed to classify patients with distinct patterns of correlation between spexin and leptin levels. Variables with substantial correlation with PC1, including spexin and leptin, were characterized for the patients in distinct cluster groups. Median and IQRs of these variables are presented by groups.
Mann-Whitney U test was used to compare the median of these variables between groups. These variables were grouped in ordinal categories of median splits for further investigating the association with cluster groups. Chi-square or Fisher exact test was used to compare the distribution. In addition, logistic regression analysis was performed to determine the association of the newly created ordinal categorical variables with cluster groups. The same analysis was performed to detect the association of the hs-CRP with cluster groups. Odds ratio and confidence intervals were calculated.
Results
Demographic, anthropometric and laboratory characteristics of the participants are provided in Table 1 . A total of 19 children with obesity (age 15.8 ± 1.7 years, BMI 36.1 ± 6.03 kg/m 2 , BMI z score 2.3 ± 0.5) were studied. Of the 19 participants, 11 had severe obesity as defined by BMI ≥ 120 per cent of the 95th percentile values or a BMI ≥ 35 kg/m 2 (whichever is lower), and 12 (63 per cent) of the participants were male. The majority of the participants were non-Hispanic white (89.5 per cent). All participants were ≥Tanner stage 4. For clarity of discussion of the new data on spexin, adipokines and related data on certain factors that were reported previously (8) were also included in Table 1 .
Median (IQR) for spexin for the patients in this study was 0.38 ng/mL (0.29-0.59 ng/mL). Spexin concentration in the study subjects was inversely correlated with leptin (Pearson correlation coefficient, r = À0.50, P = 0.03) even after adjusting for age, sex, BMI and BMI z score (Fig. 1) .The PC1 of spexin and leptin levels, which combined these two variables, accounted for 75 per cent of the variance of these two variables. This composite variable was associated positively with spexin (r = 0.87) and inversely with leptin (r = À0.87). The composite factor was also associated with insulin and hs-CRP. For insulin, the Spearman rank correlation parameters were, ρ = À0.53, P = 0.02. The means (SE) of PC1 were 0.43(.26) and À0.59(0.22) in the two hs-CRP groups of <3 mg/L and CRP > 3 mg/L, P = 0.02. Based on previous data,(9-12) we divided the participants into high risk (hs-CRP ≥ 3 mg/L) and lower risk (hs-CRP <3 mg/L) groups. Cluster analysis of the PC1 resulted in two distinct groups. Reflecting the inverse concurrence of spexin and leptin levels, one group (group 1) represented the obese patients with high spexin (median 0.62 ng/mL, IQR 0.43, 0.95) and low leptin (median 19.7 ng/mL, IQR 18.2, 32.7) levels, and the other group (group 2) represented those with low spexin (median 0.31 ng/mL, IQR 0.27, 0.40) and high leptin concentrations (median 58.2 ng/mL, IQR 48.9, 80.7). There were 8 patients in the high spexin and low leptin Spexin ng/mL
Leptin ng/mL r= -0.5 P= 0.03 Figure 1 Correlation between spexin and leptin concentrations. Relationship between spexin (ng/mL) and leptin (ng/mL) in adolescents with obesity (n = 19). Pearson correlation coefficient (r) and P-value (P) are included.
groups and 11 patients in the low spexin and high leptin groups. As expected, the spexin and leptin levels in the two groups were significantly different (P = 0.004 and P < 0.001, respectively). Potential confounders such as sex, BMI, BMI z score, fasting glucose and lipids were not significantly different in the two groups. Insulin levels were lower in group with high spexin and low leptin (median 138.9 pmol/L, IQR: 99.3 pmol/L, 254.9 pmol/L) than in the group with low spexin and high leptin (median 247.2 pmol/L, IQR: 169.5 pmol/L, 293.1 pmol/L), but these did not reach statistical significance (P = 0.091). Table 2 presents the distribution of spexin, leptin, insulin and hs-CRP for patients by cluster groups. The number of patients for lower and upper medians is presented. Odds ratio in the Table 2 compared the likelihood (odds) of having low spexin and high leptin (group 2) in patients with upper median split to the patients with lower median split for the corresponding variable. The odds (likelihood) of having the characteristics of the group with low spexin and high leptin in patients with high hs-CRP (>3 mg/L) was 12.3 times as high as it was in patients with low hs-CRP (<3 mg/L). Additionally, the odds (likelihood) of having the characteristics of the group with low spexin and high leptin in patients with high insulin (upper median split) was 2.9 times as high as it was in patients with low insulin (lower median split). However, spexin levels did not correlate with fasting glucose, HOMA-IR, lipids, total adiponectin and high molecular weight adiponectin, systolic and diastolic blood pressure, brachial FMD and reactive hyperaemia index (P > 0.05 for all).
Discussion
In the current study of post-pubertal adolescents with obesity, we demonstrate an inverse correlation between diminished circulating spexin concentration and hyperleptinaemia. Another novel finding of the study is that the adolescents with 'low spexin and high leptin' were significantly more likely to have higher levels of hs-CRP and insulin. To the best of our knowledge, these findings are novel and are being reported for the first time in children and/or adolescents. The inverse association between circulating spexin and leptin levels is novel in adolescents and/or children with obesity but similar to the sparsely available data in adults. (5) Leptin is a satiety factor produced predominantly in adipocytes and plays an active role in appetite regulation and metabolism at the level of the hypothalamus via melanocortin receptors.(13) Hyperleptinaemia in adults and children/adolescents with obesity has been consistently reported.(14-17) It reflects obesity-related leptin resistance or its lack of sensitivity for satiety related functions, potentially leading to its blunted effects on food intake. (18) (19) (20) In this context, the inverse association between spexin and leptin in the current study is important, and it is tempting to speculate that this may suggest a potential role for spexin in the regulation of body weight and energy homeostasis. In fact, in animals (rats and mice) with DIO, spexin administration has been shown to decrease caloric intake and increase locomotion.(5,7) Similarly, spexin decreased appetite in goldfish.(3) Quite intriguingly, our previous study that included normal weight Note: LEM (lower median split) contains subjects with a value less than median; GEM (upper median split) contains the subjects with a value greater than or equal to median; OR is not available (n/a) as frequency of a cell is 0. *High level of spexin and low level of leptin.
children as well as children with obesity did not show a relationship between spexin and leptin.(6) Although we do not know the exact reasons for this discrepancy, it could be related to the differences in the characteristics of study participants including age and severity of obesity. Compared with our previous study, the participants in the current study were older, more obese and with higher degrees of insulin resistance. Leptin levels were also higher among the participants in the current study than those in our previous study, likely reflecting increased leptin resistance. Indeed, it remains to be determined if the relationship between spexin and leptin is influenced by age, severity of obesity and degrees of insulin and leptin resistance. We further analysed the contrasting characteristics of spexin and leptin concentrations in the participants in the current study. When combined to form a composite factor shared by spexin and leptin, it explained >75 per cent of the variance in the dataset. Obviously, the composite variable showed strong positive and negative associations with the concentrations of spexin and leptin, respectively. More importantly, this composite variable involving spexin and leptin showed fascinating associations with hs-CRP and insulin. The likelihood of participants with high hs-CRP (>3 mg/L) was significantly higher compared with those with lower hs-CRP (<3 mg/L) to be in a subgroup of subjects typified by low spexin and high leptin vs. high spexin and low leptin. Previous studies have shown that hs-CRP concentration of ≥3 mg/L manifests significantly greater risk for CVD (9-12,21) Thus, the subgroup with 'low spexin and high leptin', which emerged from our analysis, represents a greater risk profile compared with those with 'high spexin and low leptin'. This observation is novel and important in adolescents with obesity considering the well-established fact that hs-CRP is a nonspecific, downstream marker of subclinical inflammation, and its elevated concentrations independently predict CVD events in diverse populations. (12, (21) (22) (23) (24) Various biomarkers and risk factors of CVD including elevated hs-CRP are evident in children and adolescents. (9, 12, 15, 16, (22) (23) (24) (25) (26) Additionally, puberty in children and adolescents is associated with worsening of CVD risk factors including insulin resistance and carotid intima media thickness. (12, (24) (25) (26) The composite factor shared by spexin and leptin can serve as a potential marker to stratify CVD risk in adolescents with obesity needs to be investigated in future studies with larger sample size. Further, we also observed an intriguing relationship between spexin and insulin levels as well in the current study. There was a higher chance of having the characteristics of the subgroup with 'low spexin and high leptin' in participants with high insulin concentrations compared with those with lower insulin concentrations. While we consider this as an interesting observation, this should be viewed cautiously because of the lack of direct and more sophisticated measures of insulinaemia and/or insulin resistance in the current study. On the other hand, Gu and colleagues reported lower spexin levels in adults with type 2 diabetes relative to healthy counterparts. (27) They also noted negative association between spexin and fasting blood glucose, HbA1C and triglycerides.(27) Such associations were not evident in the participants of our study, however, and these data are similar to our previous study. (6) The risk for CVD risk factors such as fasting blood glucose and fasting insulin is dependent upon the duration and severity of obesity. (12, 24) Therefore, the lack of relationships observed in the current study, in contrast to the study in adults, (27) may likely be related to the factors such as the age, duration, severity and complications of obesity in the participants in our study. The participants in the current study were overall healthier compared with the two previous studies in adults. (5, 27) Physical activity patterns also, most likely, differed in the participants in our study and those in the previous studies. (5, 27) Taken together, the relationship of spexin with leptin and presence of higher hs-CRP and insulin in those with low spexin/high leptin found in the current study warrant further investigations on the role of obesity-related 'hypospexinaemia' on long-term health implications in children and adolescents.
The pathophysiological mechanisms that link spexin with obesity, insulin resistance and CVD remain unclear. Walewski et al. reported that the gene encoding spexin (Cg12orf39) was the most downregulated gene in fat tissue in humans with obesity. (2) Circulating spexin concentrations, as well, were lower in children and adults with obesity than in their lean counterparts. (5, 6) Inverse correlations between spexin and leptin,(5) spexin and fasting glucose, glycated haemoglobin and triglycerides (27) have been reported in adults. Spexin also appears to influence energy homeostasis by altering energy consumption as well as energy expenditure. In rodents with DIO, spexin administration reduced caloric intake and resulted in weight loss.(5) Spexin also reduced adipocyte uptake of long chain fatty acids in DIO mice and improved glucose tolerance and insulin resistance in DIO mice with type 2 diabetes mellitus. (5, 7) Reductions in the concentration of liver enzymes in mouse models of hepatic steatosis have also been reported with spexin administration. (7) In this context, although preliminary, the inverse association between spexin and leptin found in the current study along with the propensity for higher levels of hs-CRP and insulin in the 'low spexin-high leptin' group suggests its potential role in obesity and risk for CVD. The current study is not designed to look at the underlying mechanisms. Interestingly, recent studies suggest that spexin-mediated multiple biological processes are likely through the activation of the galanin receptor 2 in competition with galanin. (7, 28) Important strengths of our study include the ethnic homogeneity of the participants and the absence of obesity-related comorbidities that are potential confounders. Limitations of our study include the small sample size, cross-sectional nature of the study, lack of serial measurements and the absence of a non-obese control group for comparisons. Despite the strong evidence for inverse correlation between spexin and leptin, the small number of patients in the two subgroups ('high spexin/low leptin' and 'low spexin/high leptin') resulted in limited statistical power to detect significant differences between the groups (if any) in other outcome variables. In the current study, we were able to use only the brachial artery FMD for measurement of endothelial function. Further studies should examine arterial function by using other methods including carotid intima thickness and pulse wave velocity. Another limitation, as noted above as well, was lack of a more sophisticated measurement of insulin resistance. The findings of the inverse correlation between spexin and leptin and differences in hs-CRP and insulin between the two subgroups based on spexin and leptin levels may not necessarily prove a causative role for spexin in obesity or obesity-related comorbidities such as diabetes and CVD.
Conclusion
The inverse association between spexin and leptin in adolescents with obesity and the likelihood of having higher hs-CRP and insulin concentrations in the setting of low spexin and high leptin levels found in the current study are novel. Overall, the data from the current study are intriguing and warrant further validation in larger diverse cohorts not only to further validate the clinical significance of the findings but also to delineate the underlying mechanisms involved as well.
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